BioSpace News Archive

CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has appointed Daniel Geffken as the interim chief financial officer.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2020.

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present a poster with results from a preclinical study investigating LPCN 1144 treatment on hepatic fibrosis and non-alcoholic steatohepatitis (“NASH”) features at The Liver Meeting Digital Experience™,

Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-powered cancer diagnostics, today announced that it has received ISO 13485 certification.

Heska Corporation, a leading provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments for its third quarter ended September 30, 2020.

18 abstracts spanning Jazz’s hematology/oncology therapeutic area to be presented Three abstracts selected for oral presentation, including long-term results from a Phase 3 study of Vyxeos in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announces today a correction in the time for the adjourned 2020 Annual Stockholder Meeting (“Adjourned Annual Meeting”), due to the change in daylight savings time Pacific Time in the United States

Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that the Company will release financial results of its fiscal year first quarter ended September 30, 2020 before the market opens on Thursday, November 12, 2020. The Company also will hold a conference call at 8:30 AM ET on Thursday, November 12, 2020, to discuss the results with analysts and institution

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new product incorporating FeraMAX® Pd, a new oral iron supplement delivery system, by its subsidiary BioSyent Pharma Inc. in Canada.